Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...
Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...
An Israeli study has identified TRIM63 as a significant genetic contributor to hypertrophic cardiomyopathy (HCM)—the most common hereditary heart disease worldwide. The findings, published in ...
A groundbreaking discovery from Israeli scientists is changing what doctors know about inherited heart disease. Researchers have pinpointed a gene, TRIM63, as a major contributor to hypertrophic ...
A pioneering Israeli study has identified TRIM63 as a significant genetic contributor to hypertrophic cardiomyopathy (HCM)—the most common hereditary heart disease worldwide. The findings, published ...
An analysis of two large cohort studies finds that carriers of disease-causing variants within genes for three ...
Please provide your email address to receive an email when new articles are posted on . A serum protein panel predicted risk for cardiac toxicity among childhood cancer survivors exposed to ...
COVID-19 exacerbated adverse outcomes in peripartum cardiomyopathy, increasing myocardial infarction, intensive care unit admissions, and mortality rates. Hypertrophic cardiomyopathy patients ...
Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular disorders. This often ...